Autologous cultured chondrocytes on porcine collagen membrane - Biologic Drug Details

Summary for autologous cultured chondrocytes on porcine collagen membrane

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for autologous cultured chondrocytes on porcine collagen membrane

Established Pharmacologic Class	Autologous Cultured Cell
Chemical Structure	Chondrocytes

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for autologous cultured chondrocytes on porcine collagen membrane Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for autologous cultured chondrocytes on porcine collagen membrane Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,011,811	2033-11-25	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	6,150,163	2019-01-13	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	8,029,992	2028-04-04	DrugPatentWatch analysis and company disclosures
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	8,216,778	2028-11-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for autologous cultured chondrocytes on porcine collagen membrane Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,016,338	2036-12-20	Patent claims search
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,239,927	2037-07-26	Patent claims search
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,328,126	2037-03-13	Patent claims search
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	10,533,042	2037-12-07	Patent claims search

International Patents for autologous cultured chondrocytes on porcine collagen membrane

Country	Patent Number	Estimated Expiration
Mexico	2009010694
South Korea	20090127153
World Intellectual Property Organization (WIPO)	2015077240
Hong Kong	1138374

Market Dynamics and Financial Trajectory for Autologous Cultured Chondrocytes on Porcine Collagen Membrane

Last updated: February 15, 2026

---

What is the market scope and potential for autologous cultured chondrocytes on porcine collagen membrane?

The market for autologous cultured chondrocytes combined with porcine collagen membranes targets cartilage repair, primarily for osteoarthritis and traumatic cartilage injuries. The global cartilage repair market is projected to grow from USD 4.2 billion in 2021 to USD 7.7 billion by 2030, with a CAGR of approximately 7%. The segment of biologic implants utilizing autologous cells on xenogenic scaffolds is a niche but growing component, expected to account for around 15-20% of the total cartilage repair market by 2030.

Factors influencing growth include:

• Regulatory approvals expanding indications.
• Increasing prevalence of osteoarthritis, estimated to affect over 32.5 million adults in the US alone.
• Technological advancements reducing manufacturing costs.
• Surge in clinical evidence supporting efficacy and safety.

How does the regulatory landscape impact market development?

Regulatory pathways influence commercialization timelines and investment confidence:

• United States: The FDA classifies autologous cultured chondrocyte products as human cell and tissue-based products (HCT/Ps). These must meet criteria under 21 CFR Part 1271, and approval often involves Investigational New Drug (IND) applications and subsequent Premarket Approvals (PMAs).

• Europe: The EMA classifies similar products under Advanced Therapy Medicinal Products (ATMPs). The centralized approval process involves a marketing authorization application, which can take 200 days post-submission.

• China and emerging markets: Vary regulatory requirements, often less stringent but with increasing demands for clinical data.

Regulatory variation creates market entry heterogeneity. Companies investing in R&D must align product development processes with regional compliance standards, affecting time-to-market and cost structures.

What are the manufacturing and pricing considerations?

Manufacturing involves sourcing porcine collagen and autologous chondrocytes, culture expansion, and sterilization:

• Culturing autologous cells requires specialized facilities. Costs per patient range from USD 10,000 to USD 25,000, depending on complexity, scale, and geographic factors.

• Porcine collagen, sourced from veterinary-grade pigs, costs approximately USD 50–USD 150 per gram. The product volume per implant typically ranges from 0.5 to 2 grams.

• Quality assurance and sterilization add to manufacturing overheads.

Pricing models generally feature:

• Premium pricing reflective of the minimally invasive approach and regenerative potential.
• Reimbursement schemes tied to demonstrated clinical benefits.
• Cost-effectiveness assessments favor procedures that reduce long-term healthcare expenses linked to osteoarthritis.

What is the competitive landscape?

Key players include:

• Vericel Corporation: Markets MACI (autologous cultured chondrocytes on porcine collagen membrane) with a revenue of USD 208 million in FY2022.
• Veritas Medicines: Developing novel scaffolds and cell therapies.
• Smaller biotech firms: Focus on specialized research and contract manufacturing services.

Established companies leverage existing manufacturing and distribution channels, investing heavily in clinical trials and regulatory submissions to secure approvals and reimbursement.

What are the financial projections?

Revenue estimations for the segment:

Year	Global Market Size (USD billion)	Estimated Autologous Chondrocytes on Porcine Collagen Segment (USD billion)	CAGR
2021	4.2	0.63	—
2023	5.2	0.78	7% (market CAGR)
2025	6.4	0.96	7%
2030	7.7	1.15	7%

The segment is projected to achieve higher growth rates (10%) in emerging markets due to increased adoption and flexibility in regulatory pathways.

What risks and opportunities influence market development?

Risks:

• Regulatory delays or failures.
• Clinical data inconsistencies impacting reimbursement.
• Ethical concerns surrounding xenogenic materials, including porcine collagen.
• Manufacturing scalability challenges.

Opportunities:

• Expansion into osteoarthritis and sports injury markets.
• Product innovation, such as combining with gene therapy.
• Strategic partnerships and licensing agreements for faster market entry.
• Growing patient demand for cartilage regeneration options.

---

Key Takeaways

• The market for autologous cultured chondrocytes on porcine collagen membranes is a niche with high-growth potential, driven by increasing osteoarthritis prevalence and technological improvements.
• Regulatory complexity differs geographically and impacts pricing and market access.
• Manufacturing costs remain significant but are decreasing due to process innovations.
• Competition centers around efficacy, safety, and reimbursement strategies.
• Financial growth aligns with overall cartilage repair trends, with the segment reaching USD 1.15 billion by 2030.

---

FAQs

Q1: What factors influence the pricing of autologous chondrocyte therapies on porcine collagen membranes?
Pricing reflects manufacturing costs, regulatory compliance expenses, reimbursement policies, and perceived clinical value, generally positioning these therapies as premium-priced options.

Q2: How do regulatory pathways differ globally?
The US employs the IND and PMA process under FDA regulations, while Europe relies on EMA’s ATMP approval. Emerging markets may have less stringent but evolving regulations impacting product approval timelines.

Q3: What are the main challenges in scaling manufacturing?
Ensuring consistent quality, reducing costs, and meeting stringent sterilization standards are primary challenges. Autologous cell culture also introduces variability and logistical complexities.

Q4: Which clinical outcomes most positively impact market adoption?
Significant improvements in joint function, reduced pain, and evidence of long-term durability drive adoption and reimbursement, with peer-reviewed trials serving as critical validation.

Q5: What future innovations could impact this market segment?
Integrating gene editing, advanced scaffold materials, and personalized medicine techniques may enhance efficacy, reduce costs, and open new indications.

---

References

1. Market Research Future. "Cartilage Repair Market Analysis," 2022.
2. US Food and Drug Administration. "Human Cells, Tissues, and Cellular and Tissue-Based Products," 21 CFR Part 1271.
3. European Medicines Agency. "Advanced Therapy Medicinal Products," 2022.
4. Vericel Corporation FY2022 Annual Report.
5. Global data projections based on industry reports and market analyses (internal calculations).

[1] Market Research Future, 2022; [2] FDA, 2023; [3] EMA, 2023; [4] Vericel FY2022.